Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Current hurdles in the treatment of CLL

Lindsey Roeker • 21 Dec 2018
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Venetoclax

Speaking the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, held in San Diego, CA, Lindsey Roeker, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses her perspective on the challenges facing the treatment of chronic lymphocytic leukemia (CLL). Dr Roeker highlights the need to find the best treatment combinations in the front-line setting as a key area.

More from Lindsey Roeker

6:43
Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis
Lindsey Roeker et al. • 10 Dec 2022
3:32
CLL and COVID-19: patient outcomes
Lindsey Roeker • 9 Dec 2020
2:37
Allo-HSCT for CLL in the era of novel agents
Lindsey Roeker • 7 Dec 2019
1:06
Venetoclax for treating CLL outside the clinical trial setting
Lindsey Roeker • 21 Dec 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals